Running Title: TMPRSS2:ERG and Prostate Cancer Outcomes Keywords: TMPRSS2:ERG, prostate cancer, gene fusion, biomarker, prognosis Financial Support: This work was supported by the Dana-Farber / Harvard Cancer Center Specialized Programs of Research Excellence program in prostate cancer (5P50CA090381-08);

THE TMPRSS2:ERG REARRANGEMENT, ERG EXPRESSION, AND PROSTATE CANCER OUTCOMES: A COHORT STUDY AND META-ANALYSIS Andreas Pettersson, Rebecca E. Graff, Scott R. Bauer, Michael Pitt, Rosina T. Lis, Edward C. Stack, Neil E. Martin, Lauren Kunz, Kathryn L. Penney, Azra H. Ligon, Catherine Suppan, Richard Flavin, Howard D. Sesso, Jennifer R. Rider, Christopher Sweeney, Meir Stampfer, Michelangelo Fiorentino, Philip W. Kantoff, Martin Sanda, Edward Giovannucci, Eric L. Ding, Massimo Loda, Lorelei A. Mucci *These authors contributed equally to this work Affiliations: 1) Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA 2) Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA 3) Department of Medicine, University of California San Francisco, San Francisco, CA, USA 4) Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA 5) Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA 6) Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 7) Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA 8) Department of Pathology, National University of Ireland, Galway, Galway, Ireland 9) Division of Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA 10) Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA 11) Department of Nutrition, Harvard School of Public Health, Boston, MA, USA